Mallinckrodt snaps up Sucampo for $1.2bn

Credit: IhorL

Mallinckrodt has acquired biopharma outfit Sucampo Pharmaceuticals for $1.2 billion, in one of the last major deals of 2017.

“Mallinckrodt’s acquisition of Sucampo is the latest milestone towards our vision of becoming an innovation-driven specialty pharmaceutical growth company focused on improving outcomes for patients with severe and critical conditions,” said Mark Trudeau, CEO and President of Mallinckrodt.

“The acquisition brings near-term net sales and earnings accretion through AMITIZA and bolsters our pipeline in rare diseases with VTS-270 and CPP-1X/sulindac. We look forward to adding the Sucampo portfolio and welcoming members of its team to Mallinckrodt.”